EDIT vs. BLUE

Last updated Jun 4, 2026

EDIT (Editas Medicine, Inc.) and BLUE (bluebird bio, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. At a 0.45 correlation, their price movements are largely independent.

Performance

EDIT vs. BLUE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Editas Medicine, Inc. (EDIT) and bluebird bio, Inc. (BLUE). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

EDIT

• 1D: -1.42%
• 1M: -7.33%
• YTD: 35.61%
• 6M: 17.55%
• 1Y: 52.75%
• 3Y*: -34.00%
• 5Y*: -39.28%
• 10Y*: -22.08%

BLUE

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

EDIT vs. BLUE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
EDIT Editas Medicine, Inc.	35.61%	61.42%	-87.46%	14.21%	-66.59%	-62.13%	136.78%	30.15%	-25.97%	89.34%
BLUE bluebird bio, Inc.	0.00%	-40.41%	-69.78%	-80.06%	-30.73%	-64.35%	-50.69%	-11.54%	-44.30%	188.65%

Correlation

The correlation between EDIT and BLUE is 0.45, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (3Y) Calculated over the trailing 3-year period	0.36
Correlation (5Y) Calculated over the trailing 5-year period	0.47
Correlation (10Y) Calculated over the trailing 10-year period	0.46
Correlation (All Time) Calculated using the full available price history since Feb 4, 2016	0.45

The correlation between EDIT and BLUE shifts across timeframes, from 0.36 (3 years) to 0.47 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Total Revenue (TTM) EDIT : $35.86M BLUE : $103.95M
Gross Profit (TTM) EDIT : $35.86M BLUE : $28.19M
EBITDA (TTM) EDIT : -$76.66M BLUE : -$115.82M

Return for Risk

EDIT vs. BLUE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EDIT

EDIT Risk / Return Rank: 61
EDIT Sharpe Ratio Rank: 60
EDIT Sortino Ratio Rank: 65
EDIT Omega Ratio Rank: 62
EDIT Calmar Ratio Rank: 59
EDIT Martin Ratio Rank: 57

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

EDIT vs. BLUE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Editas Medicine, Inc. (EDIT) and bluebird bio, Inc. (BLUE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	EDIT	BLUE	Difference
Sharpe ratio Return per unit of total volatility	0.56	—	—
Sortino ratio Return per unit of downside risk	1.50	—	—
Omega ratio Gain probability vs. loss probability	1.17	—	—
Calmar ratio Return relative to maximum drawdown	0.89	—	—
Martin ratio Return relative to average drawdown	1.58	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	EDIT	BLUE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.56	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.42	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.26	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.20	—	—

Drawdowns

Drawdown Indicators

	EDIT	BLUE	Difference
Max Drawdown Largest peak-to-trough decline	-98.92%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-59.88%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-91.46%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-98.66%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-98.92%	—	—
Current Drawdown Current decline from peak	-96.93%	—	—
Average Drawdown Average peak-to-trough decline	-62.56%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	33.47%	—	—

Volatility

Volatility by Period

	EDIT	BLUE	Difference
Volatility (1M) Calculated over the trailing 1-month period	30.18%	—	—
Volatility (6M) Calculated over the trailing 6-month period	61.46%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	94.33%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	93.99%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	83.75%	—	—

Dividends

EDIT vs. BLUE - Dividend Comparison

Neither EDIT nor BLUE has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both EDIT and BLUE in my portfolio?

EDIT and BLUE have a correlation of 0.45, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.